Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Chronic Hepatitis B
Interventions
DRUG

FTC/TDF

Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.

DRUG

Hepatitis B Immunoglobulin (HBIg)

HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.

Trial Locations (7)

10016

New York

10029

New York

30322

Atlanta

60608

Chicago

90048

Los Angeles

94115

San Francisco

94143

San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00507689 - Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant | Biotech Hunter | Biotech Hunter